Rigontec: Merck & Co., Inc. (NYSE:MRK) Strengthens Immuno-Oncology Portfolio With Rigontec Acquisition

Merck & Co., Inc. (NYSE:MRK) has reached an agreement for the acquisition of Rigontec, in a deal worth $137 million in cash. The deal also includes $417 million in additional payments tied to clinical, development, regulatory and commercial milestones. Rigontec Valuation Merck's valuation of Rogontec is 15 times more the $34.9 million that Rigontec raised [...]The post Merck & Co., Inc. (NYSE:MRK) Strengthens Immuno-Oncology Portfolio With Rigontec Acquisition appeared first on Market Exclusive.